Age-Related Macular Degeneration: Competitive Landscape to 2026

Age-Related macular degeneration (AMD) is one of the leading cause of vision loss among people ages 50 and over in the developed world, characterized by the deterioration or breakdown of the macula, a small area of the central retina needed for sharp central vision, gradually diminishing central vision as a result in one or both eyes.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AMD. Overall, GlobalData expects that the approval of new vascular endothelial growth factor (VEGF) inhibitors with longer efficacy duration will drive AMD market growth during the next decade; however, launching anti-VEGF biosimilars, particularly of ranibizumab, and the continued pressure from payers mandating the use of the vastly cheaper Avastin for wet AMD will curb the uptake of new anti-VEGF therapies. Additionally, two anti-complement agents for the treatment of GA will drive an increase in treated AMD cases, profoundly expanding the overall AMD market.


GlobalData’s Age-Related Macular Degeneration: Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

• Commercial Assessment—leading marketed products, current and future players

• Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global AMD market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned




Molecular Partners




Bioeq GmbH


Gene Techno Science


Chengdu Kanghong Pharmaceuticals




Shanghai Novartis Trading

Chugai Pharmaceutical

Shanghai Roche Pharmaceutical






Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview & Epidemiology

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in AMD

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.4 Japan

7.5 China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Disclaimer


Discounts available for multiple report purchases.
+44 20 7947 2745

Join our mailing list

Saved reports